Personalized Medicine: The Future is Now September 30, 2007Posted by Bertalan Meskó in Blogging, Health, Healthcare, Medicine, Personalized medicine, genetics.
During the Researchers’ Night, I gave a slideshow about personalized medicine which I’ll publish here soon. I try to use more and more tools to be able to screen the whole web for personalized medicine-related articles. So here are the most important news and announcements.
Personalized medicine based on genomics is a good thing when the patient/consumer is fully informed in advance of the implications for their own lives. Safeguards must be in place to prevent discrimination by any party based on this information.
- An other conference I have no chance to attend: Genetics and Personalized Medicine: The Future is Now on the 6th of October at the University of Kansas Edwards Campus. I at least someone will blog about it!
- Big Pharma’s personalized-medicine consortium: Is it for real? (Venture Beat):
Whatever your feelings about the drug industry, anything that might spare patients from severe drug side effects represents a step forward — not just for those who can avoid dangerous health complications, but also for the people who might be put at risk when a drug that could help them is withdrawn for safety problems that are unlikely to affect them.
- Human Genomics in the US Government (Eye on DNA):
It’s extremely encouraging to see that the government is aware of the needs and demands of the genome revolution. But, I wonder how much communication there is between the various government organizations and the degree of overlap between goals. Then there is the question of collaboration between the private sector and the government.
- Consortium to Identify Genetic Markers that Predict Drug-related Serious Adverse Events (Highlight Health):
The International Serious Adverse Events Consortium (SAEC) officially announced its formation this morning. The new global, non-profit partnership between leading pharmaceutical companies, pharmacogeneticsthe U.S. Food and Drug Administration (FDA), and academic institutions plans to identify and validate genetic markers that may help predict which individuals are at risk for serious adverse drug events.
- AMPA receptor polymorphisms add to antidepressant - suicide puzzle (Originsgenomeresources.net):
The recent paper, “Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression” finds that among 68 candidate genes, markers for 2 AMPA-type glutamate receptors show significant association in 120 individuals who experienced suicidal ideation in a large medication trial for major depressive disorder.
- Agendia Joins the Personalized Medicine Coalition (PMC) (ScientificBlogging):
Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announces that it has joint the US-based Personalized Medicine Coalition (PMC).
Read more about personalized medicine and follow Scienceroll if you want to be up-to-date in this special field of medicine.